Kyowa starts Phase II of entinostat

In October, Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) began a Phase II trial of entinostat (KHK2375, SNDX-275) in combination with exemestane in about 124 patients with advanced or recurrent hormone receptor-positive, HER2-negative breast cancer. The double-blind, placebo-controlled, Japanese trial will evaluate 5 mg entinostat weekly plus once-daily 25 mg exemestane.

The start of the trial triggered a $5 million milestone payment from Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) under a 2015 deal granting Kyowa rights to entinostat in Japan and Korea...